Format

Send to

Choose Destination
Curr Oncol Rep. 2017 Mar;19(3):19. doi: 10.1007/s11912-017-0579-4.

Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.

Author information

1
Oncology Translational and Clinical Research, Institut de Recherches Servier (IdRS), 125 Chemin de Ronde, 78290, Croissy, France.
2
Oncology Translational and Clinical Research, Institut de Recherches Internationales Servier (IRIS), 50 rue Carnot, 92284, Suresnes cedex, France. mike.burbridge@servier.com.

Abstract

A major challenge in anticancer treatment is the pre-existence or emergence of resistance to therapy. AXL and MER are two members of the TAM (TYRO3-AXL-MER) family of receptor tyrosine kinases, which, when activated, can regulate tumor cell survival, proliferation, migration and invasion, angiogenesis, and tumor-host interactions. An increasing body of evidence strongly suggests that these receptors play major roles in resistance to targeted therapies and conventional cytotoxic agents. Multiple resistance mechanisms exist, including the direct and indirect crosstalk of AXL and MER with other receptors and the activation of feedback loops regulating AXL and MER expression and activity. These mechanisms may be innate, adaptive, or acquired. A principal role of AXL appears to be in sustaining a mesenchymal phenotype, itself a major mechanism of resistance to diverse anticancer therapies. Both AXL and MER play a role in the repression of the innate immune response which may also limit response to treatment. Small molecule and antibody inhibitors of AXL and MER have recently been described, and some of these have already entered clinical trials. The optimal design of treatment strategies to maximize the clinical benefit of these AXL and MER targeting agents are discussed in relation to the different cancer types and the types of resistance encountered. One of the major challenges to successful development of these therapies will be the application of robust predictive biomarkers for clear-cut patient stratification.

KEYWORDS:

AXL; Cancer; Drug resistance; Epithelial-to-mesenchymal transition; Immunomodulation; MER

PMID:
28251492
PMCID:
PMC5332501
DOI:
10.1007/s11912-017-0579-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center